Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters

被引:6
|
作者
Koszalka, Patrycja
Szmit, Ewa
Mysliwski, Andrzej
Bigda, Jacek
机构
[1] Med Univ Gdansk, Intercollegiate Fac Biotechnol, Div Cell Biol, Dept Med Biotechnol, PL-80211 Gdansk, Poland
[2] Med Univ Gdansk, Dept Histol & Immunol, Gdansk, Poland
关键词
TNF; melanoma; tumor vasculature; immune modulation;
D O I
10.1007/s00005-007-0031-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Tumor necrosis factor (TNF) is a cytokine able to exert anti-tumor activity in various models and modes of applications. However, the exact mechanism mediating the in vivo anti-tumor effect of TNF has not yet been clarified. Materials: The effects of intratumoral injection of rat TNF into hamsters bearing Bomirski Ab amelanotic melanoma, a fast growing tumor of high metastatic potential, were tested. Subcutaneous injections of the anti-angiogenic compound TNP-470 allowed analysis of its influence on the effects of TNF administration. Results: TNF application resulted in a significant inhibition of tumor growth and changes in metastasis pattern. Accelerated hemorrhagic necrosis was also observed, indicating the effect of the cytokine on tumor vessels. Moreover, the synergistic anti-tumor effect of TNF and anti-angiogenic agent TNP-470 suggested a cooperative activity of both substances on tumor vasculature. Microscopically, the effect of TNF injections was expressed by an increase in the amount of tumor cells with nuclear pyknosis and karryorrhexis. In vitro assays indicated a direct cytotoxic effect of TNF against Ab melanoma cells, most probably as an outcome of apoptosis. Intratumoral application of TNF also caused some modulation of cytokine response in melanoma-bearing hamsters as evidenced by increased levels of IL-6 in blood serum. Conclusions: This study established Bomirski Ab melanoma as a useful model for complex analysis of the anti-tumor activity of TNF.
引用
收藏
页码:267 / 279
页数:13
相关论文
共 50 条
  • [21] Predicting the future of anti-tumor necrosis factor therapy
    Cornelis L Verweij
    Arthritis Research & Therapy, 11
  • [22] Anti-tumor necrosis factor-α medications and pregnancy
    Cristian Simon, Petru
    Vallano, Antonio
    MEDICINA CLINICA, 2013, 141 (06): : 257 - 259
  • [23] Dilated cardiomyopathy induced by anti-tumor necrosis factor
    Synetos, Andreas
    Toutouzas, Konstantinos
    Aznaouridis, Konstantinos
    Lerakis, Stamatios
    Stefanadis, Chistodoulos
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 132 (01) : E26 - E27
  • [24] Psoriasiform Reactions to Anti-Tumor Necrosis Factor α Therapy
    Nguyen, Khang
    Vleugels, Ruth Ann
    Velez, Nicole F.
    Merola, Joseph F.
    Qureshi, Abrar A.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2013, 19 (07) : 377 - 381
  • [25] Thromboembolic events and anti-tumor necrosis factor therapies
    Masson, P. L.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2012, 14 (04) : 444 - 445
  • [26] Anti-tumor necrosis factor therapy -: Experiences with Etanercept
    Nüsslein, HG
    AKTUELLE RHEUMATOLOGIE, 2000, 25 (03) : 79 - 82
  • [27] Predicting the future of anti-tumor necrosis factor therapy
    Verweij, Cornelis L.
    ARTHRITIS RESEARCH & THERAPY, 2009, 11 (03)
  • [28] Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action
    Feldmann, M
    Brennan, F
    Paleolog, E
    Taylor, P
    Maini, RN
    EUROPEAN CYTOKINE NETWORK, 1997, 8 (03) : 297 - 300
  • [29] Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
    Ulrike Billmeier
    Walburga Dieterich
    Markus F Neurath
    Raja Atreya
    World Journal of Gastroenterology, 2016, (42) : 9300 - 9313
  • [30] Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
    Billmeier, Ulrike
    Dieterich, Walburga
    Neurath, Markus F.
    Atreya, Raja
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (42) : 9300 - 9313